摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 4,5-dimethyl-2-ethoxycarbonylaminothiophene-3-carboxylate | 62349-15-9

中文名称
——
中文别名
——
英文名称
ethyl 4,5-dimethyl-2-ethoxycarbonylaminothiophene-3-carboxylate
英文别名
2-ethoxycarbonylamino-4,5-dimethyl-thiophene-3-carboxylic acid ethyl ester;Ethyl 2-ethoxycarbonylamino-4,5-dimethyl-3-thiophenecarboxylate;ethyl 2-(ethoxycarbonylamino)-4,5-dimethylthiophene-3-carboxylate
ethyl 4,5-dimethyl-2-ethoxycarbonylaminothiophene-3-carboxylate化学式
CAS
62349-15-9
化学式
C12H17NO4S
mdl
MFCD03380538
分子量
271.337
InChiKey
BPOHIOJADPELPE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    70-72 °C(Solv: ethanol (64-17-5))
  • 沸点:
    337.7±42.0 °C(Predicted)
  • 密度:
    1.223±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    18
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    92.9
  • 氢给体数:
    1
  • 氢受体数:
    5

SDS

SDS:6d34856c27002e147bc6cd9627389c76
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Syntheses of substituted 2,4-dioxo-thienopyrimidin-1-acetic acids and their evaluation as aldose reductase inhibitors
    摘要:
    A series of 2,4-dioxo-thieno[2,3-d], [3,2-d] and [3,4-d]pyrimidin-1-acetic acids (2) with a benzyl moiety at the N-3 position were prepared and tested in vitro for aldose reductase inhibitory activity against partially purified enzyme from rat lens. Some of these compounds were also evaluated for inhibition of sorbitol accumulation in the sciatic nerve or lens of streptozotocin-induced diabetic rats in vivo. Among the synthesized compounds, several showed potent aldose reductase inhibitory activity with IC50s in the 10(-8) M range. Particularly, the potencies of non-substituted thieno- (2a and 2aa), 5-methylthieno- (2c), 5,6-dimethylthieno-(2g), 6-isopropylthieno- (2j and 2k), 6-chlorothienopyrimidine (2q) and benzothienopyrimidine (2ac) analogs were approximately equipotent to FK-366 (1A) and Ponalrestat (1B) as references. Although most compounds were inactive in vivo, 2 compounds, 2k and 2q, possessed moderate in vivo activity.
    DOI:
    10.1016/0223-5234(93)90112-r
  • 作为产物:
    描述:
    氯甲酸乙酯2-氨基-4,5-二甲基噻吩-3-羧酸乙酯 反应 3.0h, 以86%的产率得到ethyl 4,5-dimethyl-2-ethoxycarbonylaminothiophene-3-carboxylate
    参考文献:
    名称:
    Syntheses of substituted 2,4-dioxo-thienopyrimidin-1-acetic acids and their evaluation as aldose reductase inhibitors
    摘要:
    A series of 2,4-dioxo-thieno[2,3-d], [3,2-d] and [3,4-d]pyrimidin-1-acetic acids (2) with a benzyl moiety at the N-3 position were prepared and tested in vitro for aldose reductase inhibitory activity against partially purified enzyme from rat lens. Some of these compounds were also evaluated for inhibition of sorbitol accumulation in the sciatic nerve or lens of streptozotocin-induced diabetic rats in vivo. Among the synthesized compounds, several showed potent aldose reductase inhibitory activity with IC50s in the 10(-8) M range. Particularly, the potencies of non-substituted thieno- (2a and 2aa), 5-methylthieno- (2c), 5,6-dimethylthieno-(2g), 6-isopropylthieno- (2j and 2k), 6-chlorothienopyrimidine (2q) and benzothienopyrimidine (2ac) analogs were approximately equipotent to FK-366 (1A) and Ponalrestat (1B) as references. Although most compounds were inactive in vivo, 2 compounds, 2k and 2q, possessed moderate in vivo activity.
    DOI:
    10.1016/0223-5234(93)90112-r
点击查看最新优质反应信息

文献信息

  • 3-Amino-thieno- und -[1]benzothieno[2,3-d]pyrimidin-derivate
    作者:Fritz Sauter、Peter Stanetty、Hans Potužak
    DOI:10.1002/ardp.19763091109
    日期:——
    In 2‐Stellung basisch substituierte Derivate des 3‐Amino‐thieno[2,3‐d]pyrimidin‐4(3H)‐ons (allg. Formel I) sowie des 3‐Amino‐5.6.7.8‐tetrahydro‐[1]benzothieno[2,3‐d]pyrimidin‐4(3H)‐ons (allg. Formel II) wurden dadurch synthetisiert, daß die entsprechend substituierten 2‐Acylamino‐thiophen‐ (bzw. ‐benzo[b]thiophen‐) carbonsäureester 1a–1o hergestellt und diese mittels Hydrazin in einer einstufigen Reaktion
    3-氨基-噻吩并[2,3-d]嘧啶-4(3H)-one(通式I)和3-氨基-5.6.7.8-四氢-[1]苯并噻吩的衍生物在2-中具有碱性取代基[2,3-d] 嘧啶-4 (3H) -ones(通式II)是通过相应取代的2-酰氨基-噻吩-(或-苯并[b]噻吩-)羧酸酯1a合成的– 1o 和这些在一步反应中使用肼进行取代和环化,得到目标化合物。
  • Thienopyrimidine derivaties as aldose-reductase inhibitors
    申请人:Taiho Pharmaceutical Company, Limited
    公开号:US04898867A1
    公开(公告)日:1990-02-06
    The present invention provides thienopyrimidine derivatives of the formula (I) ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represent hydrogen, halogen, lower alkyl, cycloalkyl or phenyl, R.sub.1 and R.sub.2 taken together may form a ring of an alkylene chain, R.sub.3 represents lower alkyl or a group of the formula ##STR2## (in which R.sub.4 is a lower alkyl, lower alkoxy or halogen, m is 0, 1 or 2, and R.sub.5 is hydrogen or halogen) and Z is oxygen or sulfur, or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as an active principle and aldose-reductase inhibitors.
    本发明提供了式(I)的噻唑嘧啶衍生物,其中R.sub.1和R.sub.2相同或不同,且分别表示氢、卤素、较低的烷基、环烷基或苯基,R.sub.1和R.sub.2在一起可以形成一个烷基链的环,R.sub.3表示较低的烷基或式子##STR2##的基团(其中R.sub.4为较低的烷基、较低的烷氧基或卤素,m为0、1或2,R.sub.5为氢或卤素),Z为氧或硫,或其药学上可接受的盐,以及包含它们作为活性原料的药物组成物和醛糖还原酶抑制剂。
  • THIENOPYRIMIDINE DERIVATIVES
    申请人:TAIHO PHARMACEUTICAL COMPANY, LIMITED
    公开号:EP0335979A1
    公开(公告)日:1989-10-11
    Thienopyrimidine derivatives represented by general formula (I), wherein R1 and R2, which may be the same or different, each represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic alkyl group or a phenyl group, or R1 and R2 may be bound to each other to form an alkylene chain for forming a ring, R3 represents a lower alkyl group or a group of formula (II) (wherein R4 represents a lower alkyl group, a lower alkoxy group or a halogen atom, m represents 0, 1 or 2 and Rs represents a hydrogen atom or a halogen atom) or pharmaceutically acceptable salts thereof, a pharmacological composition containing the same as effective ingredient, and an aldose reductase inhibitor are disclosed.
    由通式(I)代表的噻吩嘧啶衍生物,其中 R1 和 R2 可以相同或不同,各自代表氢原子、卤素原子、低级烷基、环状烷基或苯基,或者 R1 和 R2 可以相互结合形成亚烷基链以形成环、R3 代表低级烷基或式(II)基团(其中 R4 代表低级烷基、低级烷氧基或卤素原子,m 代表 0、1 或 2,Rs 代表氢原子或卤素原子)或其药学上可接受的盐、含有其作为有效成分的药物组合物以及醛糖还原酶抑制剂。
  • Ogawva K., Yamawaki I., Matsusita Y. I., Nomura N., Kador P. F., Kinoshit+, Eur. I. Med. Chem, 28 (1993) N 10, S 769-781
    作者:Ogawva K., Yamawaki I., Matsusita Y. I., Nomura N., Kador P. F., Kinoshit+
    DOI:——
    日期:——
  • US4898867A
    申请人:——
    公开号:US4898867A
    公开(公告)日:1990-02-06
查看更多

同类化合物

阿罗洛尔 阿替卡因 阿克兰酯 锡烷,(5-己基-2-噻吩基)三甲基- 邻氨基噻吩(2盐酸) 辛基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 辛基4,6-二溴噻吩并[3,4-b]噻吩-2-羧酸酯 辛基2-甲基异巴豆酸酯 血管紧张素IIAT2受体激动剂 葡聚糖凝胶LH-20 苯螨噻 苯并[c]噻吩-1-羧酸,5-溴-4,5,6,7-四氢-3-(甲硫基)-4-羰基-,乙基酯 苯并[b]噻吩-2-胺 苯并[b]噻吩-2-胺 苯基-[5-(4,4,5,5-四甲基-[1,3,2]二氧杂硼烷-2-基)-噻吩-2-基亚甲基]-胺 苯基-(5-氯噻吩-2-基)甲醇 苯乙酸,-α--[(1-羰基-2-丙烯-1-基)氨基]- 苯乙酰胺,3,5-二氨基-a-羟基-2,4,6-三碘- 苯乙脒,2,6-二氯-a-羟基- 腈氨噻唑 聚(3-丁基噻吩-2,5-二基),REGIOREGULAR 硝呋肼 硅烷,(3-己基-2,5-噻吩二基)二[三甲基- 硅噻菌胺 盐酸阿罗洛尔 盐酸阿罗洛尔 盐酸多佐胺 甲酮,[5-(1-环己烯-1-基)-4-(2-噻嗯基)-1H-吡咯-3-基]-2-噻嗯基- 甲基5-甲酰基-4-甲基-2-噻吩羧酸酯 甲基5-乙氧基-3-羟基-2-噻吩羧酸酯 甲基5-乙基-3-肼基-2-噻吩羧酸酯 甲基5-(氯甲酰基)-2-噻吩羧酸酯 甲基5-(氯乙酰基)-2-噻吩羧酸酯 甲基5-(氨基甲基)噻吩-2-羧酸酯 甲基5-(4-甲氧基苯基)-2-噻吩羧酸酯 甲基5-(4-甲基苯基)-2-噻吩羧酸酯 甲基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 甲基4-硝基-2-噻吩羧酸酯 甲基4-氰基-5-(4,6-二氨基吡啶-2-基)偶氮-3-甲基噻吩-2-羧酸酯 甲基4-氨基-5-(甲硫基)-2-噻吩羧酸酯 甲基4-{[(2E)-2-(4-氰基苯亚甲基)肼基]磺酰}噻吩-3-羧酸酯 甲基4-(氯甲酰基)-3-噻吩羧酸酯 甲基4-(氨基磺酰基氨基)-3-噻吩羧酸酯 甲基3-甲酰氨基-4-甲基-2-噻吩羧酸酯 甲基3-氨基-5-异丙基-2-噻吩羧酸酯 甲基3-氨基-5-(4-溴苯基)-2-噻吩羧酸酯 甲基3-氨基-4-苯基-5-(三氟甲基)-2-噻吩羧酸酯 甲基3-氨基-4-氰基-5-甲基-2-噻吩羧酸酯 甲基3-氨基-4-丙基-2-噻吩羧酸酯 甲基3-[[(4-甲氧基苯基)亚甲基氨基]氨基磺酰基]噻吩-2-羧酸酯